F Street

TDCX Inc. Enters into Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Friday, March 1, 2024

The Company’s board of directors (the “Board”), acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger.

Key Points: 
  • The Company’s board of directors (the “Board”), acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.
  • The Company will furnish to the U.S. Securities and Exchange Commission (the “SEC”) a current report on Form 6-K regarding the Merger, which will include as an exhibit thereto the Merger Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the “Schedule 13E-3”) to its shareholders.

The Museum of Illusions Washington DC Opens December 13th

Retrieved on: 
Tuesday, November 8, 2022

WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Tickets for the The Museum of Illusions Washington DC (925 H Street NW) are now available to purchase, starting at $23.95. Be one of the first to experience the new and exciting museum, the 40th to open globally. As the newest addition to CityCenterDC, MOIDC offers a totally original, educational and instagrammable experience to visitors of all ages. The more than 50 interactive exhibits will debut on December 13, 2022. The museum's unique hands-on experience is designed to include illusionistic rooms, optical illusions and a playroom with didactic games and puzzles. All exhibits on science, mathematics and psychology allow visitors to learn about vision, perception, and the human brain through interaction and fun.

Key Points: 
  • WASHINGTON, Nov. 8, 2022 /PRNewswire/ --Tickets for the The Museum of Illusions Washington DC (925 H Street NW) are now available to purchase , starting at $23.95.
  • The museum's unique hands-on experience is designed to include illusionistic rooms, optical illusions and a playroom with didactic games and puzzles.
  • "We are thrilled to be opening the Museum of Illusions in Washington DC, providing both residents and visitors with a completely unique and immersive experience unlike anything else in the district," said Ghida Damirji, MOIDC's owner.
  • In the heart of Washington DC, The Museum of Illusions offers guests an unforgettable and mind-bending experience, testing the limits of the human brain's perception.

Glory Star Enters into a Definitive Agreement for Going-Private Transaction

Retrieved on: 
Monday, July 11, 2022

As of the date of the Merger Agreement, the Buyer Group beneficially owns, in the aggregate, approximately 72.8% of the outstanding Shares of the Company.

Key Points: 
  • As of the date of the Merger Agreement, the Buyer Group beneficially owns, in the aggregate, approximately 72.8% of the outstanding Shares of the Company.
  • Since its establishment in 2016, Glory Star has been laser focused on developing an ecosystem for its users that incorporates quality content, e-commerce, social networking, and gaming.
  • Glory Star also provides a suite of tools for its users to facilitate the development of new content by creators.
  • Statements that are not historical facts, including statements about Glory Star's beliefs and expectations, are forward-looking statements.

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.
  • On April 19, 2022, Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock.
  • On May 2, 2022, Scandinavian Acquisition Sub, Inc., a wholly owned subsidiary of Regeneron, commenced a tender offer for all of the outstanding shares of Checkmate common stock.
  • Research and development expenses (R&D): R&D expenses for the first quarter of 2022 were $11.6 million, compared to $10.4 million for the same period in the prior year.

RenovaCare Announces Termination of StemCell Systems R&D Agreement

Retrieved on: 
Tuesday, May 3, 2022

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities.

Key Points: 
  • No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities.
  • This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events.
  • There can be no assurance that further research and development will validate and support the results of our preliminary research and studies.
  • You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330.

W. P. Carey Announces Proposed Merger with CPA®:18 in a $2.7 Billion Transaction

Retrieved on: 
Monday, February 28, 2022

The transaction has also been approved by CPA:18's Board of Directors upon the unanimous recommendation of a Special Committee of CPA:18's independent directors.

Key Points: 
  • The transaction has also been approved by CPA:18's Board of Directors upon the unanimous recommendation of a Special Committee of CPA:18's independent directors.
  • Upon closing of the merger, W. P. Carey stockholders and CPA:18 stockholders will own approximately 93% and 7% of the combined company, respectively.
  • Furthermore, it will essentially conclude our exit from Investment Management, further simplifying our business and enhancing our scale."
  • The proxy statement/prospectus will describe in greater detail the terms of the proposed merger.

Berkshire Hathaway HomeServices California Properties’ New Homes Division Became Favorite of Builders and Developers in 2021

Retrieved on: 
Friday, February 4, 2022

San Diego, CA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The New Homes Division of Berkshire Hathaway HomeServices California Properties continued its growth streak in 2021, with its agents becoming the favorite sales representative of many builders and developers throughout Southern California.

Key Points: 
  • San Diego, CA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The New Homes Division of Berkshire Hathaway HomeServices California Properties continued its growth streak in 2021, with its agents becoming the favorite sales representative of many builders and developers throughout Southern California.
  • A wealth of support flows to the New Homes Division from Berkshire Hathaway HomeServices California Properties, including one-stop mortgage, escrow, title services, and an in-house legal department.
  • Berkshire Hathaway HomeServices California Properties proudly supports 3,000 sales associates in 45 offices spanning Santa Barbara to San Diego.
  • Berkshire Hathaway HomeServices California Properties is a wholly owned subsidiary of HomeServices of America, Inc., and a member of HSF Affiliates, LLC.

Colfax Announces Plans for Reverse Stock Split

Retrieved on: 
Thursday, December 30, 2021

WILMINGTON, DE, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it plans to hold a special meeting of stockholders to seek approval for an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect, at the discretion of the Board of Directors, (i) a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at one of three reverse stock split ratios, one-for-two, one-for-three or one-for-four, with the exact ratio to be determined by the Board of Directors of the Company at a later date, and (ii) if and when the reverse stock split is effected, a corresponding reduction in the number of authorized shares of our Common Stock by the selected reverse stock split ratio.

Key Points: 
  • WILMINGTON, DE, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (Colfax or the Company) (NYSE: CFX), a leading diversified technology company, announced today that it plans to hold a special meeting of stockholders to seek approval for an amendment to the Companys Amended and Restated Certificate of Incorporation (the Certificate of Incorporation) to effect, at the discretion of the Board of Directors, (i) a reverse stock split of the Companys common stock, par value $0.001 per share (the Common Stock), at one of three reverse stock split ratios, one-for-two, one-for-three or one-for-four, with the exact ratio to be determined by the Board of Directors of the Company at a later date, and (ii) if and when the reverse stock split is effected, a corresponding reduction in the number of authorized shares of our Common Stock by the selected reverse stock split ratio.
  • Colfax will hold a special meeting of stockholders on February 28, 2022 to seek approval of the reverse stock split and the corresponding authorized share count reduction.
  • Even if the reverse stock split proposal is approved by the Companys stockholders, the Board of Directors may delay or abandon the reverse stock split at any time prior to the effective time of the reverse stock split if the Board of Directors determines that the reverse stock split is no longer in the best interests of the Company or its stockholders.
  • In connection with the Reverse Split Proposal, Colfax plans to file a preliminary proxy statement on Schedule 14A with the SEC.

Management Acquires SolarWindow Majority Ownership

Retrieved on: 
Tuesday, December 14, 2021

Mr. Rhee also serves as director and shareholder of LQE, the new majority stockholder of SolarWindow.

Key Points: 
  • Mr. Rhee also serves as director and shareholder of LQE, the new majority stockholder of SolarWindow.
  • I believe that SolarWindow products and technologies have an exciting future ahead, and wish to thank our former controlling stockholder for supporting SolarWindow development in the years past.
  • Mr. Rayat founded, funded, and has supported SolarWindow operations and development of its technologies with more than $30 million in equity investment.
  • Since then, the Company has further strengthened its new management and expanded SolarWindow operations to South Korea, culminating with the management-led transaction announced today under the leadership of Mr. John Rhee.

Dawson Geophysical Announces Letter To Shareholders Regarding Tender Offer

Retrieved on: 
Tuesday, November 16, 2021

MIDLAND, Texas, Nov. 16, 2021 /PRNewswire/ -- Dawson Geophysical Company (NASDAQ: DWSN) ("Dawson" or the "Company") today released the following letter to shareholders concerning the pending tender offer by Wilks Brothers, LLC issued by Stephen C. Jumper, President and Chief Executive Officer on behalf of the Dawson Board of Directors.

Key Points: 
  • MIDLAND, Texas, Nov. 16, 2021 /PRNewswire/ -- Dawson Geophysical Company (NASDAQ: DWSN) ("Dawson" or the "Company") today released the following letter to shareholders concerning the pending tender offer by Wilks Brothers, LLC issued by Stephen C. Jumper, President and Chief Executive Officer on behalf of the Dawson Board of Directors.
  • The transaction involves a tender offer by a Wilks subsidiary to purchase outstanding Dawson common shares at $2.34 per share and a follow-on merger.
  • The solicitation and offer to buy the Company's stock is only being made pursuant to the Offer to Purchase and related tender offer materials.
  • THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CONTAIN IMPORTANT INFORMATION.